Drug class
18F-labelled amyloid beta PET radiotracer; diagnostic imaging agent
Mechanism of action
Binds aggregated amyloid beta plaques in the brain. PET detects tracer distribution to estimate amyloid pathology; imaging is an adjunct to clinical assessment and does not itself diagnose Alzheimer disease.
General use cases
- PET imaging of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer disease or other causes of cognitive decline
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
